A breakthrough in biofilm prevention for DENTAL implants + ORTHOPEDIC components


Reduces bacterial adhesion and biofilm on dental implants + supports cleaner implant surfaces in high-risk oral environments

Reduces bacterial adhesion on orthopedic components + supports safer device performance by targeting inflammation- and infection-related risks

  • Reduces bacterial adhesion & biofilm formation – decreasing infection & inflammation risk
  • Acts passively – no antibiotics, silver or active biological agents
  • Chemically stable – commercially scalable
  • Suitable for several device materials including titanium and stainless steel
  • Compatible with standard sterilisation methods
  • Patented & available for licensing

Nilbax™

Independent laboratory testing confirms Nilbax® reduces bacterial adhesion and biofilm formation on coated titanium + anodised titanium surfaces


broad-spectrum protection

When applied to titanium, Nilbax® significantly reduces biofilm formation across a wide range of organisms.

Samples were incubated for 24 hours in static overnight cultures of Candida albicans, gram-positive or gram-negative bacteria, then stained with crystal violet to highlight the biofilm forming on each surface.



reducing bacterial adhesion

Nilbax® creates a barrier on the surface of dental and orthopedic implants and components, reducing the likelihood of post-procedure inflammation and infection.

Titanium samples were incubated with Staphylococcus aureus for 24 hours in static culture, washed extensively to remove loosely bound bacteria, then fixed for microscopic image analysis. The analysis confirmed a 2-log reduction in adhered bacteria on Nilbax®-coated titanium.



lasting protection under flow

A flow cell moves fresh culture across the surface continuously, which is closer to conditions in the mouth than a static dish.

Anodised titanium abutments were exposed to a mixed culture of five oral bacteria (Streptococcus mutans, Actinomyces naeslundii, Veillonella dispar, Fusobacterium nucleatum and Porphyromonas gingivalis) in a flow cell for 10 days. Uncoated abutments developed dense, established biofilm, while Nilbax®-coated abutments remained largely clear, with a 5-fold average reduction in biofilm.

Anodised titanium implant posts tested under the same conditions showed a 10-fold average reduction.



integrates normally with bone

A coating that keeps bacteria off an implant must not get in the way of healing.

In a rat femoral bone model, Nilbax®-coated and uncoated titanium screws were assessed at 14, 28 and 56 days after insertion, using torsional fixation testing, peri-implant bone volume and bone mineral density.

Nilbax® showed no evidence of impaired bone integration or screw fixation in this model.


TekCyte works with leading innovators across medical, biotech and industrial sectors to bring advanced coating science into real-world application.

We have collaborated with organisations including Saint-Gobain, Cynata Therapeutics, Alyra Biotech and Osmoflo.

Using world-leading surface technologies, the TekCyte team contributes deep technical expertise and scientific insight to a wide range of commercial projects and research collaborations, supporting both early-stage innovation and commercial-scale integration.

These collaborations reflect our reputation for high-quality, flexibility and results-driven execution in addressing complex surface challenges.

Using world-leading surface technologies, the TekCyte team contributes their extensive knowledge and know-how to a diverse range of commercial projects and research collaborations.

SAHMRI
Adelaide University
Saint-Gobain
Cynata Therapeutics
University of Sheffield
University of Queensland
Osmoflo
Alyra Biotech
Hydroxsys
ReNerve